Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com


Related Content

News | Cardiovascular Ultrasound

May 30, 2024 — A recent study published in the European Heart Journal highlights the significant enhancements that the ...

Home May 30, 2024
Home
News | Cardiovascular Ultrasound

April 5, 2024 — Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound ...

Home April 05, 2024
Home
News | Cardiovascular Ultrasound

August 24, 2023 —Royal Philips, a global leader in health technology, highlighted how it integrates AI in cardiac ...

Home August 24, 2023
Home
News | Cardiovascular Ultrasound

July 27, 2023 —UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial ...

Home July 27, 2023
Home
Feature | Cardiovascular Ultrasound

February 10, 2023 — GE HealthCare, a leading global precision care innovator, announced that it has signed an agreement ...

Home February 10, 2023
Home
Feature | Cardiovascular Ultrasound | By Paul M Bojarski

Sudden cardiac arrest is a complex and challenging medical emergency because it can occur anywhere at any time and is ...

Home August 23, 2022
Home
News | Cardiovascular Ultrasound

August 9, 2022 — Butterfly Medical, an Israeli medical device company developing a novel minimally invasive solution to ...

Home August 09, 2022
Home
News | Cardiovascular Ultrasound

July 20, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced the first patient ...

Home July 20, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

Enhanced features on the Philips EPIQ CVx ultrasound system provide a next level photorealistic 3D rendering, making it ...

Home July 20, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

Automated features on the Philips EPIQ CVx cardiology ultrasound system are helping to bring consistency and speed to ...

Home July 07, 2022
Home
Subscribe Now